As of the latest data point for Q3'25, Pfizer's Operating ROA stands at 1.70%, with ROE at 3.82% and ROIC at 2.14%. This reflects a modest improvement in profitability metrics compared to the previous quarter, with all three ratios showing positive values after some volatility in prior periods. Analyzing the trend from Q1'23 to Q3'25, the chart reveals significant fluctuations across all metrics. ROA, ROE, and ROIC experienced notable declines into negative territory in late 2023, indicating operational challenges. However, from early 2024 onward, there is a gradual recovery, with most metrics returning to positive levels and stabilizing through 2025, except for a sharp outlier in ROIC at Q4'24. Overall, the data suggests a period of volatility followed by a steady rebound in operating performance.